Loss or mutation of OBSCN has been implicated in: brain tumors, oral squamous cell carcinoma, gastrointestinal tract cancers, Wilms tumor, renal cell carcinoma, female reproductive cancers (ovarian, endometrial), prostate cancer, breast cancer and melanoma. This evidence concerns the gene OBSCN and hereditary clear cell renal cell carcinoma.